Walbert Keli has filed 5 insider transactions across 2 companies since January 2025.
Most recent transaction: a grant/award of 7961 shares of Apellis Pharmaceuticals, Inc. ($APLS) on January 01, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 1, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Walbert Keli | Director | A | Common Stock | 7961 | $0.00 | 17,051.0000 | 130,067,000 | 87.58% | 0.01% |
| Jan. 1, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Walbert Keli | Director | A | Stock Option (Right to Buy) | 14684 | $0.00 | 14,684.0000 | 130,067,000 | 9999.99% | 0.01% |
| Dec. 11, 2025 | SPRUCE BIOSCIENCES, INC. | $SPRB | Walbert Keli | Not found | A | Stock Option (Right to Buy) | 3400 | $0.00 | 3,400.0000 | 1,070,370 | 9999.99% | 0.32% |
| Jan. 8, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Walbert Keli | Director | A | Common Stock | 9090 | $0.00 | 9,090.0000 | 123,905,000 | 9999.99% | 0.01% |
| Jan. 8, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Walbert Keli | Director | A | Stock Option (Right to Buy) | 15388 | $33.00 | 15,388.0000 | 123,905,000 | 9999.99% | 0.01% |